Olsalazine

Summary

Olsalazine (CHEMBL425) is an approved small molecule (ATC A07EC03); indicated across 1 condition including ankylosing spondylitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A07EC03
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 302.24 Da · C14H10N2O6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL425
Name	Olsalazine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	22419
ATC	A07EC03
Molecular formula	C14H10N2O6
Molecular weight	302.24
InChIKey	QQBDLJCYGRGAKP-UHFFFAOYSA-N

SMILES: C1=CC(=C(C=C1N=NC2=CC(=C(C=C2)O)C(=O)O)C(=O)O)O

IUPAC name: 5-[(3-carboxy-4-hydroxyphenyl)diazenyl]-2-hydroxybenzoic acid

Also known as: C. i. mordant yellow 5, Olsalazina, Olsalazine, olsalazine, SID50125747, OLSALAZINE, SID225144315

Parent form; salt/anhydrous children: CHEMBL1201013

Patent coverage: 3,934 distinct patent families (16,848 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 16,779 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Menin/Histone-lysine N-methyltransferase MLL, 3’,5’-cyclic-AMP phosphodiesterase 4A, Vascular endothelial growth factor receptor 2, Flavin reductase (NADPH), Huntingtin.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 6 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
BLVRB	7.16	Kd	70	nM	CHEMBL_ACT_24380457
BLVRB	7.15	Kd	70.79	nM	CHEMBL_ACT_24380458

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
ankylosing spondylitis	2	MONDO:0005306	EFO:0003898

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00004288	PHASE2	COMPLETED	Phase II Pilot Study of Olsalazine for Ankylosing Spondylitis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).